uniQure N.V. QURE
Updated: 17 Jun 2026
No signal published yet
We already track uniQure N.V. and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow uniQure N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow uniQure N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 5, 2026, uniQure reported first-quarter financial results and confirmed plans to submit a Marketing Authorisation Application for AMT-130 in the UK during the third quarter of 2026. The company also scheduled a Type B meeting with the FDA for the second quarter of 2026 to discuss the clinical development path for its Huntington's disease program. These updates follow positive 36-month data from Phase I/II trials showing slowed disease progression.
What Firelda Watch includes for uniQure N.V.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow uniQure N.V.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow uniQure N.V. free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more